Covalent Group has signed a $1.7 million contract for a Phase II trial assessing the potential benefit of aggressive anti-microbial therapy in inhibiting progression of atherosclerosis in subjects with known vascular disease. Atherosclerosis is a disease affecting the arterial blood vessels throughout the body. The trial will utilize data recorded from serial images obtained with multiple medical imaging techniques. The imaging data will be analyzed in with clinical assessments and biomarke...